Yahoo MoviesTop plays from LA Clippers vs. Sacramento Kings
Top plays from LA Clippers vs. Sacramento Kings, 01/20/2021
Top plays from LA Clippers vs. Sacramento Kings, 01/20/2021
GENEVA — The World Health Organization’s Europe unit is reporting that about one in 10 people who contracted COVID-19 continue to show “persistent ill health” 12 weeks after infection. Dr. Hans Kluge, the head of WHO Europe, says much about so-called “long COVID” remains unknown, but the “burden is real, and it is significant.” In a policy brief released on Thursday, WHO Europe urged policymakers to do more to acknowledge and treat long COVID, which can bring severe fatigue, chest pain, heart inflammation, headache, forgetfulness, depression, loss of smell, recurrent fever, diarrhea and ringing in the ears. It said available data showed that about one in four people with COVID-19 show symptoms about a month after testing positive, while one in 10 experience symptoms after 12 weeks. Kluge told reporters that the coronavirus is still spreading at “very high rates” across the 53-country European region, citing two variants of concern. However, he said fewer than 1 million new cases have been reported for a second straight week and transmission is slowing. ___ THE VIRUS OUTBREAK: — Medical oxygen scarce for coronavirus patients in Africa, Latin America — Republicans solidly against $1.9 trillion COVID-19 relief bill with decision looming on minimum wage increase — Flu virtually disappears in U.S. this season, with COVID-19 precautions likely preventing both illnesses — EU summit to tackle why the 27-nation bloc's vaccine rollout has been so slow — Qantas expects to resume international flights in October, after Australian population is vaccinated — Follow all of AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic, https://apnews.com/hub/coronavirus-vaccine and https://apnews.com/UnderstandingtheOutbreak ___ HERE’S WHAT ELSE IS HAPPENING: PARIS — Family doctors in France have started giving COVID-19 vaccine shots vulnerable people between the ages of 50 and 64 as the country works to speed up its vaccination program against the coronavirus. Vaccines administrated by doctors are reserved to those with pre-existing health condition that make them more susceptible to complications of COVID-19 if they become infected. France has started its vaccination campaign on Dec. 27 in nursing homes. Since then, it has opened hundreds of vaccination centres across the country to provide vaccines to people over age 75 and health care workers. Making vaccines available to the next category of recipients through family doctors starting Thursday marks the next step in the vaccination rollout. Doctors are allowed to administer the AstraZeneca vaccine at their practice offices or at patients' workplaces. French authorities have reported over 85,000 deaths from the virus since the beginning of the pandemic, one of the highest tolls in Europe. ___ ALGIERS, Algeria — Algeria’s national public television network says the country has received a batch of COVID-19 vaccines donated by China to help fight the pandemic. Images broadcast on TV showed a military jet carrying the Sinopharm vaccines had landed on Wednesday evening in the presence of Algerian Minister of Communication Ammar Belhimer and Chinese Ambassador Li Lianhe. China has donated 200,000 vaccines to Algeria. They come in addition to the North African nation’s purchase of 50,000 doses of Russia’s Sputnik V vaccine and 50,000 doses of the AstraZeneca vaccine. Algerian has reported 2,967 coronavirus-related deaths and more than 112,000 confirmed cases. COPENHAGEN, Denmark — Finland plans to reintroduce a state of emergency that would allow the Nordic country to close restaurants for a three-week period starting March 8 as it fights the variant first discovered in Britain. “I know you’re tired. So am I. But we have to be strong and now the situation is more difficult,” Prime Minister Sanna Marin told a press conference on Thursday. The variant “is more difficult to tackle, the old tools are not enough. Closed borders are not enough.” The new measures require students over 13 to switch to distance learning and halts their leisure activities. A public meeting ban for more than six people is introduced and people are urged to avoid private gatherings. People in Finland would still have to work remotely and wear face masks. A formal text will be presented next week before parliament. In March, Finnish lawmakers adopted the emergency powers to tackle the coronavirus crisis. The country has seen 757 virus deaths in the pandemic ___ AMSTERDAM — Amsterdam is restricting access to a large park after thousands of people gathered there Wednesday, many of them flouting social distancing rules. With warm spring weather in the Netherlands expected to continue through much of Thursday, the side entrances to Amsterdam’s Vondelpark will be closed and City Hall says it is closely monitoring the main gates. The municipality says if it gets too busy in the lawns and ponds close to the city’s museums neighbourhood then the park will be completely closed. The city says it “will not accept deliberate breaches of the rules with all the ensuing risks to public health.” The Netherlands has been in a tough lockdown since mid-December. Public support for the measures has been eroding in recent weeks as numbers of infections have steadily declined. Despite a rise in infections over the past week, the government on Tuesday announced that high school students will be allowed back to their classrooms starting next Monday for at least one day per week. Businesses such as hair and beauty salons also will reopen. ___ BERLIN — A silver lining to coronavirus lockdown measures: with fewer motor vehicles, bicycles and pedestrians out on the streets, German authorities are reporting the lowest number of traffic fatalities since they started keeping statistics. The Federal Statistical Office reported Thursday that in 2020, 2,724 people died due to traffic accidents in Germany, 10.6% fewer than in 2019 and the lowest number since the Wiesbaden-based agency started keeping such tallies more than 60 years ago. “This is in particular due to the fact that due to the coronavirus pandemic, significantly fewer kilometres were driven on German roads in 2020 than the previous year,” the agency said. The numbers were particularly low during the early part of the year and at the end of the year when Germany had instituted strict lockdown measures, and ticked upward in the summer when the measures were relaxed. ___ PRAGUE — The Czech government is barring its citizens and residents from travelling to countries hit by highly contagious coronavirus variants and is tightening rules for face coverings. Starting Thursday, people are required to wear better masks in places where large numbers gather, including stores, hospitals and public transportation. Cloth masks will no longer be good enough and medical-grade masks, safety respirators or two surgical masks will have to be used instead. The changes come as one of the hardest-hit European Union countries faces a surge of a fast-spreading coronavirus variant originally found in Britain. As of Friday, Czechs and foreign residents are not allowed to travel to 11 countries amid concerns over coronavirus variants first detected in South Africa and Brazil. The Cabinet is also preparing new restrictions that Prime Minister Andrej Babis indicated will include limits on movement. The country’s day-to-day increase in new confirmed cases reached 13,657 on Wednesday, about 2,700 more than a week ago. The nation of 10.7 million had almost 1.2 million cases with 19,835 deaths. ___ NAIROBI, Kenya — The Africa Centers for Disease Control and Prevention director is warning it would be a “fatal mistake” if the developed world takes the attitude of “we’ll vaccinate our people, and people in other parts of the world can take care of their own." John Nkengasong, speaking Thursday to reporters, added that “it’s in no one’s interest we continue to be in this tense situation” and said more could have been done to address the global COVID-19 vaccine inequality. But he celebrated that Ghana has become the first country in the world to receive vaccines via the global COVAX effort aimed at distributing doses to low-income countries. He said he hoped vaccinations would start Thursday in Ghana and that vaccine deliveries to other African countries will arrive in the coming days. Africa over the past month has seen a decrease in the number of new cases after a strong resurgence in infections driven by a more infectious variant of the coronavirus discovered in South Africa. The continent surpassed 100,000 confirmed COVID-19 deaths this month. ___ ISLAMABAD — Pakistan will resume regular classes five days per week at all schools from March 1 amid a steady decrease in COVID-19 deaths and cases from coronavirus. Education Minister Shafqat Mahmood made the announcement Thursday on Twitter. Pakistan closed classrooms in November amid a surge in infections. Later schools were opened in phases, but regular classes had not been allowed. Authorities said Wednesday that they will allow opening of parks, cinemas and indoor dining and wedding receptions beginning on March 15. Pakistan has reported 12,772 deaths from the coronavirus. Pakistan is currently vaccinating health workers and elderly people using the Sinopharm vaccine donated by China. ___ TAIPEI, Taiwan — Taiwan will begin slightly easing restrictions on foreign visitors coming to the island beginning Monday. The Central Epidemic Command Center says foreign nationals wishing to come to Taiwan for business can apply for special permission at the island’s representative offices abroad. They will need to show negative coronavirus test results obtained three days before they travel and will be tested again after undergoing two weeks of quarantine. Travellers from a list of countries and regions classified as being of low or medium risk for COVID-19 can apply for shortened quarantine periods of between five and seven days. Those include New Zealand, Macao, Australia, Singapore, Vietnam and Cambodia. Rule changes will also allow for foreigners in travel groups to change flights in Taiwan, and make it easier for Chinese citizens to visit for personal reasons and for Chinese students to return to Taiwanese institutions of higher education. Taiwan instituted stricter measures on Jan. 1 to guard against variants of the coronavirus. The island of 23 million has recorded just 946 cases and nine deaths from COVID-19. ___ JUNEAU, Alaska — Alaska House Speaker Louise Stutes says a member of the Alaska House has tested positive for the virus that causes COVID-19. She asked members and staff not to enter the Capitol on Thursday unless necessary to allow for contact tracing and cleaning to occur. Further details weren’t immediately available. The announcement came the same day that Alaska Gov. Mike Dunleavy’s office announced he had COVID-19. His office says the 59-year-old Republican is in quarantine at his home with mild symptoms. At least nine U.S. state governors have tested positive for the coronavirus. ___ WELLINGTON, New Zealand — New Zealand’s success in battling the coronavirus has unleashed an unanticipated problem: skyrocketing house prices. When the pandemic first hit, most experts predicted house prices would fall. Instead, prices have risen by more than 19% over the past year, putting them out of reach for many people wanting to buy their first home. The government, which has come under increasing criticism for its response to the housing squeeze, on Thursday announced the first of what it says will be a series of moves to address the issue by ordering the nation’s central bank to consider the impact on house prices when making decisions. Reserve Bank Governor Adrian Orr said it welcomed the new directive, which is “in tune” with its own advice to the government. New Zealand has managed to stamp out community spread of the virus, allowing most aspects of life to return to normal, and its economy has rebounded strongly as a result. GDP grew by a record 14% in the December quarter, erasing most of the virus-induced contraction from earlier last year. Unemployment remains at a relatively low 4.9%. ___ LOS ANGELES — Los Angeles County is reporting another 806 deaths from coronavirus during the winter surge, pushing California’s toll above 50,000, or about one-tenth of the U.S. total from the pandemic. The county, which has a quarter of the state’s 40 million residents, said Wednesday that it checked backlogged death records and found the deaths, most of which occurred between December and early this month. Johns Hopkins University puts California’s overall COVID-19 death toll at 50,890. The grim figure comes just days after the U.S. recorded a half-million deaths. ___ WASHINGTON — President Joe Biden plans to distribute millions of face masks to Americans in communities hard-hit by the coronavirus. It’s part of his effort to ensure equity in the government’s response to the pandemic. Biden is aiming to reach underserved communities and those bearing the brunt of the outbreak. His plan will distribute masks not through the mail, but through Federally Qualified Community Health Centers and the nation’s food bank and food pantry systems. The White House announced it expects more than 25 million American-made cloth masks in both adult and kid sizes will be distributed. Biden has asked everyone to wear face masks for the first 100 days of his term. He’s also required mask-wearing in federal buildings and on public transportation. The Associated Press
Covid world map: which countries have the most coronavirus vaccinations, cases and deaths?. Covid-19 has spread around the planet, sending billions into lockdown. Find out where the virus has spread, and where it has been most deadly
The pair received ‘substantial compensation’ and a public apology from Mirror Group Newspapers.
The Global Tobacco Market size is expected to reach $1,066. 6 billion by 2026, rising at a market growth of 3. 6% CAGR during the forecast period. Tobacco is an economically significant agricultural crop which is grown across the world.New York, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Tobacco Market By Product, By Region, Industry Analysis and Forecast, 2020 - 2026" - https://www.reportlinker.com/p06028136/?utm_source=GNW India is one of the largest producers and exporters of tobacco after China and Brazil. Consumption of tobacco in any form results in health risks & complications. The higher number of passive smokers are affected majorly due to the Tobacco consumption. The highly addictive nature of nicotine makes it difficult for the smokers to quit the tobacco consumption. Irrespective of the fact that tobacco causes serious harm to the health, tobacco industry is still booming due to its economic importance. The cultivation of Tobacco is largely in the southern states of India, as weather is suitable for the cultivation of the crop.In recent years, the global increment in the number of smokers has been witnessed. New product launches which include numerous flavored tobacco products like menthol cigars & clove cigarettes is one of the major factors boosting the trend of tobacco consumption. This aspect is anticipated to fuel the market growth over the forecasted period. In addition, the increasing preference of smoking alternatives leads to the launch of innovative tobacco products with unique tastes options has been witnesses across the globe. Due to this factor, manufacturers are planning to launch premium tobacco products added with flue-cured tobacco and fine whole leaf.By ProductBased on Product, the market is segmented into Cigarettes, Cigar & Cigarillos, Next Generation Products, Water Pipes, Smokeless Tobacco and Other Products. The cigarettes segment acquired the prominent market share in 2019. The cigarette refers to a cylinder-shaped product that contain psychoactive material like tobacco rolled into thin paper. The consumption of cigarettes is increasing in developing countries and decreasing in the higher income countries. China is considered as one of the largest cigarette markets in the globe. In addition, the introduction of different types of flavors in the cigarette will further boost the adoption of cigarettes across the globe.By RegionBased on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. Asia-Pacific is among the largest producers & consumers of tobacco across the globe. The leading companies of the region are China and India. Four largest tobacco companies in the world are China National Tobacco Corporation, PT GudangGaramTbk, Japan Tobacco Inc., and ITC Limited are from Asia-Pacific. China is the biggest market in this region & the country is known for the significant portion of the population who are the consumers of tobacco products. of the easy availability of the tobacco products in contemporary retail outlets in this region acts as the major factor boosting the growth of the tobacco market in this region.The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Japan Tobacco, Inc., and British American Tobacco PLC are the forerunners in the Tobacco Market. Companies such as Swedish Match AB, Altria Group, Inc., Scandinavian Tobacco Group A/S, Korea Tobacco & Ginseng Corporation are some of the key innovators in the market.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Old Holdco, Inc. (Pyxus International, Inc.), Swedish Match AB, Altria Group, Inc. (Philips Morris International, Inc.), Korea Tobacco & Ginseng Corporation (KT&G Corporation), British American Tobacco PLC, Japan Tobacco, Inc. (Government of Japan), Scandinavian Tobacco Group A/S, ITC Limited, Eastern Company S.A.E, and Imperial Brands PLC.Strategies deployed in Tobacco MarketPartnerships, Collaborations, and Agreements:Sep-2020: Japan Tobacco extended its partnership with Sauber Engineering AG (SEN), a leading player in technology and prototype development. In this extended partnership, the companies continued their collaboration for the development of precision engineering projects focused on increasing the performance of the next generation of JT Group products.Aug-2020: Korea Tobacco & Ginseng Corporation signed an agreement with Philip Morris International, a Swiss-American multinational cigarette and tobacco manufacturing company. In this agreement, Philip Morris commercializes KT&G’s smoke-free alternatives outside of South Korea. Philip Morris launched KT&G’s lil SOLID device and its complementing Fiit consumables in Russia. Lil SOLID is a device that uses a pin-based tobacco heating system developed to offer four consecutive experiences without recharging.Feb-2020: Pyxus International Inc. came into partnership with Turning Point Brands Inc., Louisville-based tobacco products company. Under the partnership, the companies agreed to share certain research and testing data to make the foundation of certain respective premarket tobacco product applications before the submission to the U.S. Food and Drug Administration. Moreover, Turning Point Brands signed a supply agreement for its house brands of e-cigarette liquids.Jul-2019: Imperial Brands partnered with Auxly Cannabis Group, a vertically integrated cannabis company. Under this partnership, the companies work together in research and development and provide the Vancouver firm with the global licenses to the British tobacco giant’s vaping technology. The partnership also enhanced Imperial Brands’ ability to implement their business strategies which further boosts their growth plans.Feb-2019: Eastern Company renewed its agreement with British American Tobacco (BAT) and Mansour International Distribution Co. In this agreement, Eastern produces foreign Target cigarettes in its partnership with Mansour. Similarly, the company also produces Pall Mall and Viceroy cigarettes in its partnership with BAT.Acquisition and Mergers:Nov-2020: British American Tobacco took over the nicotine pouch product assets of Dryft Sciences LLC. This acquisition expanded British American Tobacco’s modern oral portfolio in the US from 4 to 28 variants. The improved portfolio includes a broad range of nicotine products and flavors that offers a greater degree of choice, covering all potential consumer preferences.Apr-2020: Scandinavian Tobacco Group completed the acquisition of Agio Cigars, owned by Agio Beheer BV. Through this acquisition, Scandinavian Tobacco aimed to gain substantial growth in sales and marketing, production, and back-office functions.Jun-2019: Altria came into an agreement to acquire Burger Söhne, a provider of tobacco products. Under this acquisition, Altria acquired 80 percent of certain companies of Burger Söhne. It commercialized ON! products globally, which is an oral tobacco-derived nicotine (TDN) pouch product. Following the acquisition, the company will get access to the leading products and brands in the moist smokeless tobacco, heated tobacco, and e-vapor categories. The acquisition would add another non-combustible product to Altria’s portfolio, which has a high-potential, significantly developing oral TDN products group.Nov-2018: Japan Tobacco took over the Akij Group’s tobacco business. This acquisition accelerated the expansion of the company in the emerging market.Jul-2018: Swedish Match agreed to acquire Gotlands Snus AB, a privately held Swedish company. The acquisition would expand Swedish Match’s business and improve their presence with the production in Gotland. Gotlands Snus complemented Swedish Match’s portfolio and offered an increased depth to their offerings.Sep-2017: Swedish Match took over V2 Tobacco, a privately held smokeless tobacco company. V2 Tobacco´s modern and adaptable production enabled Swedish Match to enhance flexibility and expanded the opportunities to adapt to changing consumer desires. Swedish Match further worked toward its vision of a world without cigarettes.Sep-2017: Japan Tobacco completed its acquisition of Mighty Corporation, a tobacco company. Following the acquisition, Japan Tobacco expanded its geographical footprints. It also provided the distribution network in the Philippines to Japan tobacco and strengthened the brand’s portfolio with the addition of brands like Mighty and Marvels.Aug-2017: Japan Tobacco came into an agreement to acquire PT. Karyadibya Mahardhika, a kretek cigarette company and its distributor, PT. Surya Mustika Nusantara. The acquisition aims to expand the global presence of Japan Tobacco in the market.Jul-2017: British American Tobacco completed its acquisition of Reynolds American, an American tobacco company. The acquisition helped the company is positioning itself as a strong, global tobacco and Next Generation Products company, which delivers sustained long-term profit growth and returns.Product Launches and Product Expansions:Oct-2019: Marlboro, a division of Altria is developing a new tobacco device, Iqos. This device heats the tobacco instead of burning it, which gives customers the same rush of nicotine as smoking with some toxins.Jan-2019: Japan Tobacco launched Ploom TECH+, a low-temperature tobacco vapor product, and Ploom S, a high-temperature tobacco vapor product. Both of the new products were added to the online store and retail stores of the company across Japan. These products are highly adopted by the consumers because of their no tobacco smoke smell and better usability.Scope of the StudyMarket Segments covered in the Report:By Product• Cigarettes• Cigar & Cigarillos• Next Generation Products• Water Pipes• Smokeless Tobacco• Other ProductsBy Geography• North Americao USo Canadao Mexicoo Rest of North America• Europeo Germanyo UKo Franceo Russiao Spaino Italyo Rest of Europe• Asia Pacifico Chinao Japano Indiao South Koreao Singaporeo Malaysiao Rest of Asia Pacific• LAMEAo Brazilo Argentinao UAEo Saudi Arabiao South Africao Nigeriao Rest of LAMEACompanies Profiled• Old Holdco, Inc. (Pyxus International, Inc.)• Swedish Match AB• Altria Group, Inc. (Philips Morris International, Inc.)• Korea Tobacco & Ginseng Corporation (KT&G Corporation)• British American Tobacco PLC• Japan Tobacco, Inc. (Government of Japan)• Scandinavian Tobacco Group A/S• ITC Limited• Eastern Company S.A.E• Imperial Brands PLCUnique Offerings • Exhaustive coverage• Highest number of market tables and figures• Subscription based model available• Guaranteed best price• Assured post sales research support with 10% customization freeRead the full report: https://www.reportlinker.com/p06028136/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
25 February 2021 LEI: 2138003QW2ZAYZODBU23 LSE Code: QQQS WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY(a public company incorporated with limited liability in Ireland)WISDOMTREE NASDAQ 100® 3X DAILY SHORT SECURITIESPROPOSED AMENDMENT TO THE PRINCIPAL AMOUNT OF THE AFFECTED SECURITIES MEETING OF THE ETP SECURITYHOLDERS THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about what action you should take, you are recommended to consult your independent financial adviser. If you have sold or transferred all of your WisdomTree NASDAQ 100® 3x Daily Short Securities (the “Affected Securities”) of WisdomTree Multi Asset Issuer Public Limited Company (the “Issuer”), please send this document, together with the accompanying form of proxy, at once to the purchaser or transferee or stockbroker, banker or other agent through whom the sale or transfer was made, for onward transmission to the purchaser or transferee. The Issuer wishes to announce that the Meeting of the holders of the Affected Securities (with ISIN IE00BLRPRJ20) scheduled for 25 February 2021 at 11:00 a.m. (the “Original Meeting”) has been adjourned, in accordance with paragraph 20 of Schedule 7 of the Trust Deed, for lack of a quorum. The adjourned meeting will be reconvened at 11:00 a.m. on Friday 12 March 2021, being a date not less than 14 calendar days and not more than 42 days after the Original Meeting, and will be held by way of virtual meeting (the “Adjourned Meeting”). The Adjourned Meeting is being held to consider certain amendments to documentation, made under the powers set out in clause 2 of schedule 7 of the master trust deed of the Affected Securities, required to effect a reduction in the principal amount of the Affected Securities from USD 12.18 to USD 1.218. This follows the price of the Affected Securities falling below 500 per cent. of its current principal amount on Tuesday 26 January 2021, and is designed to maintain the normal trading and operations of the Affected Securities. Full details of the Proposal and Extraordinary Resolution are set out in the notice dated 2 February 2021. It is important to note that: The reduction of the Principal Amount of the Affected Securities does NOT dilute an Affected Security Holder’s holding or reduce the value of an Affected Security Holder’s holding. The reduction of the Principal Amount does NOT negatively impact the ability of the investor to trade the Affected Securities. The reduction of the Principal Amount does NOT affect the amount an Affected Security Holder would, in practice, receive on redemption of the Affected Securities. Holders of the Affected Securities have received a form of proxy by post, directing them to submit their voting instructions through the relevant ICSD or the relevant participant in an ICSD on the matters being considered at the Original Meeting and at the Adjourned Meeting. Under article 11.5 of the Issuer’s Articles of Association, no further notification is required for the Adjourned Meeting. Holders of the Affected Securities are therefore directed to the original notification posted to them on 2 February 2021, and also available on the website of the Issuer, at https://www.wisdomtree.eu/en-gb/-/media/eu-media-files/other-documents/operational/corp-action/boost/rns-corporate-actions/qqqs---pa-reduc---initial-notice-2-feb-2021_final.pdf. Holders of the Affected Securities will not be permitted to attend the Adjourned Meeting physically in person, and are strongly advised to vote by proxy. In case of queries in relation to proxy voting, please contact Link Asset Services at enquiries@linkgroup.ie. If holders of the Affected Securities wish to attend the Adjourned Meeting, arrangements will be made for them to attend virtually via such teleconference facility as shall be specified by the chairperson ahead of the Adjourned Meeting. Holders of the Affected Securities who wish to attend the Adjourned Meeting in this way are directed to contact Apex IFS Limited at IFSCOSEC@apexfs.com no later than half an hour before the Adjourned Meeting, and will require proof of identity and holding. Holders of the Affected Securities should note that a duly completed form of proxy deposited in respect of the Original Meeting will continue to be valid for the Adjourned Meeting unless previously revoked or suspended by a further form of proxy prior to the Adjourned Meeting. In accordance with normal practice, The Law Debenture Trust Corporation p.l.c., as trustee, expresses no opinion as to the merits of the Proposal, the terms of which were not negotiated by it. It has however authorised it to be stated that, on the basis of the information contained in the original circular and in this document (which it advises holders of Affected Securities to read carefully) it has no objection to the form in which the Proposal and Notice of Meeting are presented to holders of Affected Securities for their consideration. Holders of the Affected Securities will be notified of the outcome of the Adjourned Meeting shortly thereafter.
“At least half of my patients say that they’re waiting for us to get it before they get it from anywhere,” the head of Tryon Medical said.
EyeSouth Partners ("EyeSouth" or the "Company") is pleased to announce that it has completed an affiliation with North Georgia Eye Clinic ("NGEC"). The affiliation represents EyeSouth’s ninth in the state of Georgia and twenty-second affiliation overall. EyeSouth is an eye care-focused management services organization backed by Shore Capital Partners, committed to partnering with leading physicians to build a premier network of eye care services in the U.S. EyeSouth’s affiliate network consists of 22 practices with nearly 200 doctors providing medical and surgical eye care services at over 100 locations including 13 surgery centers throughout Georgia, Texas, Louisiana, Florida, Tennessee, Ohio, Kentucky and Alabama.
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Playtika Holding Corp (NASDAQ:PLTK) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 8:30 AM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Element Solutions, Inc. (NYSE:ESI) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 8:30 AM Eastern Time.
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 8:30 AM Eastern Time.
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / MediWound Ltd. (NASDAQ:MDWD) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 8:30 AM Eastern Time.
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Safran SA (OTC PINK:SAFRY) will be discussing their earnings results in their 2020 Second Half Earnings call to be held on February 25, 2021 at 8:30 AM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.
American Woodmark Corporation (NASDAQ: AMWD) (the "Company") today announced results for its third fiscal quarter ended January 31, 2021.
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / TECSYS, Inc. (OTC PINK:TCYSF) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on February 25, 2021 at 8:30 AM Eastern Time.
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / MTBC, Inc. (NASDAQ:MTBC) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 8:30 AM Eastern Time.
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Gladstone Land Corp. (NASDAQ:LAND) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 8:30 AM Eastern Time.
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / TPG RE Finance Trust, Inc. (NYSE:TRTX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 8:30 AM Eastern Time.
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Pacira Biosciences, Inc. (NASDAQ:PCRX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 8:30 AM Eastern Time.
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / EPR Properties (NYSE:EPR) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 8:30 AM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.
Fourth quarter 2020 revenues of $711.2 million, up 4.4% versus prior year period on an as-reported basis; up 2.3% on a constant currency basis Fourth quarter 2020 GAAP diluted EPS from continuing operations of $1.62, compared to $2.28 in the prior year period Fourth quarter 2020 adjusted diluted EPS from continuing operations of $3.25, down 0.9% versus prior year period Full year 2020 revenues of $2.537 billion, down 2.2% versus prior year period on an as-reported basis; down 2.4% on a constant currency basis Full year 2020 GAAP diluted EPS from continuing operations of $7.10, compared to $9.81 in the prior year period Full year 2020 adjusted diluted EPS from continuing operations of $10.67, down 4.3% versus prior year period 2021 guidance range for GAAP revenue growth of between 10.0% and 11.5% 2021 guidance range for constant currency revenue growth of between 8.0% and 9.5% 2021 guidance range for GAAP diluted EPS from continuing operations of between $8.15 and $8.25 2021 guidance range for adjusted diluted EPS from continuing operations of between $12.50 and $12.70 WAYNE, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2020. Fourth quarter 2020 net revenues were $711.2 million, an increase of 4.4% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, fourth quarter 2020 net revenues increased 2.3% over the year ago period. The Company estimates that COVID-19 had a net negative impact to fourth quarter 2020 revenue of approximately $61 million, or 9%. Fourth quarter 2020 GAAP earnings per share from continuing operations decreased 28.9% to $1.62, compared to $2.28 in the prior year period. Fourth quarter 2020 adjusted diluted earnings per share from continuing operations decreased 0.9% to $3.25, compared to $3.28 in the prior year period. Full year 2020 net revenues were $2.537 billion, a decrease of 2.2% compared to the prior year. Excluding the impact of foreign currency exchange rate fluctuations, full year 2020 net revenues decreased 2.4% over the prior year. The Company estimates that COVID-19 had a net negative impact to full year 2020 revenue of approximately $281 million, or 11%. Full year 2020 GAAP earnings per share from continuing operations decreased 27.6% to $7.10, compared to $9.81 in the prior year. Full year 2020 adjusted diluted earnings per share from continuing operations decreased 4.3% to $10.67, compared to $11.15 in the prior year. Liam Kelly, Chairman, President and Chief Executive Officer, said, “Due to the COVID-19 pandemic, 2020 was a difficult year for Teleflex. However, during the fourth quarter our business performed better than we expected, as trends continued to improve across many of our product categories and geographies." Mr. Kelly continued, "In addition to the significant sequential improvement in our constant currency revenue performance that we experienced in the fourth quarter, I am also very pleased to see the continued sequential improvement that occurred in both our adjusted gross and adjusted operating margins, as we believe this positions us well to achieve our longer-term financial objectives." Mr. Kelly concluded, "As we look forward to 2021, despite the ongoing COVID-19 pandemic, we remain confident in our diversified product portfolio and in our ability to deliver robust revenue growth, margin expansion and adjusted earnings growth, all while investing in our business to sustain our revenue growth and profitability profile over the long-term." NET REVENUE BY SEGMENT The following tables and commentary provide information regarding net revenues in each of the Company's reportable operating segments for the three and twelve months ended December 31, 2019 and December 31, 2020 on both a GAAP and constant currency basis. The discussion below the tables of the principal factors behind changes in net revenues for the three months ended December 31, 2020 as compared to the prior year period applies to both GAAP revenue and constant currency revenue, although GAAP revenue also was affected by foreign currency exchange rate fluctuations, as indicated in the "Currency Impact" column of the table. Three Months Ended % Increase / (Decrease) December 31, 2020 December 31, 2019 Total Sales Growth Currency Impact Constant Currency Revenue Growth Americas$419.5 $400.0 4.9% (0.1)% 5.0%EMEA 161.4 145.9 10.6% 6.5% 4.1%Asia 78.6 80.5 (2.3)% 4.9% (7.2)%OEM 51.7 54.6 (5.5)% 1.4% (6.9)%Total$711.2 $681.0 4.4% 2.1% 2.3% Twelve Months Ended % Increase / (Decrease) December 31, 2020 December 31, 2019 Total Sales Growth Currency Impact Constant Currency Revenue Growth Americas$1,465.0 $1,492.3 (1.8)% (0.2)% (1.6)%EMEA 584.9 588.1 (0.5)% 1.1% (1.6)%Asia 267.0 294.3 (9.3)% 0.3% (9.6)%OEM 220.3 220.7 (0.2)% 0.4% (0.6)%Total$2,537.2 $2,595.4 (2.2)% 0.2% (2.4)% Americas fourth quarter 2020 net revenues were $419.5 million, an increase of 4.9% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, fourth quarter 2020 net revenues increased 5.0% compared to the prior year period. The increase in constant currency revenue was primarily attributable to increased sales volumes of existing and new products, partially offset by a net decrease in sales volumes of existing products caused by the COVID-19 pandemic. We estimate that COVID-19 had a negative impact to fourth quarter 2020 revenue of approximately $29 million, or 7%. EMEA fourth quarter 2020 net revenues were $161.4 million, an increase of 10.6% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, fourth quarter 2020 net revenues increased 4.1% compared to the prior year period. The increase in constant currency revenue was primarily attributable to increased sales volumes of existing products, partially offset by a net decrease in sales volumes of existing products caused by the COVID-19 pandemic. We estimate that COVID-19 had a negative impact to fourth quarter 2020 revenue of approximately $1 million, or 1%. Asia fourth quarter 2020 net revenues were $78.6 million, a decrease of 2.3% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, fourth quarter 2020 net revenues decreased 7.2% compared to the prior year period. The decrease in constant currency revenue was primarily attributable to a net decrease in sales volumes of existing products caused by the COVID-19 pandemic. We estimate that COVID-19 had a negative impact to fourth quarter 2020 revenue of approximately $10 million, or 12%. OEM fourth quarter 2020 net revenues were $51.7 million, a decrease of 5.5% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, fourth quarter 2020 net revenues decreased 6.9% compared to the prior year period. The decrease in constant currency revenue was primarily attributable to a decrease in sales volumes of existing products caused by the COVID-19 pandemic, partially offset by net revenues generated by the acquisition of IWG High Performance Conductors, Inc. (HPC). We estimate that COVID-19 had a negative impact to fourth quarter 2020 revenue of approximately $21 million, or 38%. NET REVENUE BY GLOBAL PRODUCT CATEGORY The following tables and commentary provide information regarding net revenues in each of the Company's global product categories for the three months and twelve months ended December 31, 2019 and December 31, 2020 on both a GAAP and constant currency basis. Three Months Ended % Increase / (Decrease) December 31, 2020December 31, 2019 Total Revenue Growth Currency Impact Constant Currency Revenue GrowthVascular Access$182.5$154.6 18.0 % 2.0% 16.0 %Interventional 106.7 112.7 (5.3)% 1.6% (6.9)%Anesthesia 86.1 85.3 0.9 % 3.0% (2.1)%Surgical 92.3 95.2 (3.0)% 2.7% (5.7)%Interventional Urology 93.9 89.1 5.4 % 0.1% 5.3 %OEM 51.7 54.6 (5.5)% 1.4% (6.9)%Other 98.1 89.4 9.8 % 3.7% 6.1 %Total$711.2$681.0 4.4 % 2.1% 2.3 % Twelve Months Ended % Increase / (Decrease) December 31, 2020December 31, 2019 Total Revenue Growth Currency Impact Constant Currency Revenue GrowthVascular Access$657.7$600.9 9.5 % 0.1% 9.4 %Interventional 382.4 427.6 (10.6)% 0.1% (10.7)%Anesthesia 302.3 338.4 (10.7)% 0.2% (10.9)%Surgical 317.2 370.1 (14.3)% 0.2% (14.5)%Interventional Urology 290.0 290.4 (0.1)% 0.1% (0.2)%OEM 220.3 220.7 (0.2)% 0.4% (0.6)%Other 367.3 347.3 5.8 % 0.5% 5.3 %Total$2,537.2$2,595.4 (2.2)% 0.2% (2.4)% Fourth quarter 2020 net revenues from sales of Vascular Access products were $182.5 million, an increase of 18.0% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, fourth quarter 2020 net revenues increased 16.0% compared to the prior year period. We estimate that COVID-19 had a net positive impact to fourth quarter 2020 revenue of approximately $7 million, or 5%. Fourth quarter 2020 net revenues from sales of Interventional products were $106.7 million, a decrease of 5.3% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, fourth quarter 2020 net revenues decreased 6.9% compared to the prior year period. We estimate that COVID-19 had a negative impact to fourth quarter 2020 revenue of approximately $14 million, or 12%. Fourth quarter 2020 net revenues from sales of Anesthesia products were $86.1 million, an increase of 0.9% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, fourth quarter 2020 net revenues decreased 2.1% compared to the prior year period. We estimate that COVID-19 had a negative impact to fourth quarter 2020 revenue of approximately $1 million, or 1%. Fourth quarter 2020 net revenues from sales of Surgical products were $92.3 million, a decrease of 3.0% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, fourth quarter 2020 net revenues decreased 5.7% compared to the prior year period. We estimate that COVID-19 had a negative impact to fourth quarter 2020 revenue of approximately $9 million, or 9%. Fourth quarter 2020 net revenues from sales of Interventional Urology products were $93.9 million, an increase of 5.4% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, fourth quarter 2020 net revenues increased 5.3% compared to the prior year period. We estimate that COVID-19 had a negative impact to fourth quarter 2020 revenue of approximately $25 million, or 28%. Fourth quarter 2020 net revenues from sales of OEM products were $51.7 million, a decrease of 5.5% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, fourth quarter 2020 net revenues decreased 6.9% compared to the prior year period. We estimate that COVID-19 had a negative impact to fourth quarter 2020 revenue of approximately $21 million, or 38%. Fourth quarter 2020 net revenues from sales of other products were $98.1 million, an increase of 9.8% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, fourth quarter 2020 net revenues increased 6.1% compared to the prior year period. We estimate that COVID-19 had a positive impact to fourth quarter 2020 revenue of approximately $1 million, or 1%. OTHER FINANCIAL HIGHLIGHTS AND KEY PERFORMANCE METRICS Depreciation expense, amortization of intangible assets and deferred financing charges for the year ended December 31, 2020 totaled $231.7 million compared to $218.4 million for the prior year. Cash and cash equivalents at December 31, 2020 were $375.9 million compared to $301.1 million at December 31, 2019. Net accounts receivable at December 31, 2020 were $395.1 million compared to $418.7 million at December 31, 2019. Net inventories at December 31, 2020 were $513.2 million compared to $476.6 million at December 31, 2019. Net cash provided by operating activities from continuing operations was $437.1 million during 2020, as compared to $437.1 million during 2019. In 2020, the cash flow from operations reflect an increase in contingent consideration payments and tax payments that were mainly offset by favorable changes in other working capital. The favorable changes in other working capital were driven mainly by higher accounts receivable collections. 2021 OUTLOOK On a GAAP basis, full year 2021 revenues are expected to increase between 10.0% and 11.5% over 2020, reflecting our estimate of an approximately 2% favorable impact of foreign currency exchange rate fluctuations. On a constant currency basis, the Company estimates that revenues for full year 2021 will increase between 8.0% and 9.5% over 2020. The Company expects full year 2021 GAAP diluted earnings per share from continuing operations to be between $8.15 and $8.25. The Company expects adjusted diluted earnings per share from continuing operations to be between $12.50 and $12.70 for full year 2021, representing an increase of between 17.2% and 19.0% over 2020. Forecasted 2021 Constant Currency Revenue Growth Reconciliation LowHigh Forecasted 2021 GAAP revenue growth10.0%11.5% Estimated impact of foreign currency exchange rate fluctuations2.0%2.0% Forecasted 2021 constant currency revenue growth8.0%9.5% Forecasted 2021 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation LowHigh Forecasted GAAP diluted earnings per share from continuing operations$8.15 $8.25 Restructuring, restructuring related and impairment items, net of tax$0.60 $0.61 Acquisition, integration and divestiture related items, net of tax$0.13 $0.14 Other items, net of tax$0.17 $0.19 MDR$0.48 $0.50 Intangible amortization expense, net of tax$2.97 $3.01 Forecasted adjusted diluted earnings per share from continuing operations$12.50 $12.70 CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION As previously announced, Teleflex will comment on its financial results on a conference call to be held today at 8:00 a.m. (ET). The call will be available live and archived on the Company’s website at www.teleflex.com and the accompanying presentation will be posted prior to the call. An audio replay will be available until March 2, 2021 at 11:00am (ET), by calling 855-859-2056 (U.S./Canada) or 404-537-3406 (International), Passcode: 8789956. ADDITIONAL NOTES References in this release to the impact of foreign currency exchange rate fluctuations on adjusted diluted earnings per share include both the impact of translating foreign currencies into U.S. dollars and the impact of foreign currency exchange rate fluctuations on foreign currency denominated transactions. In the discussion of segment results, "new products" refers to products for which we initiated commercial sales within the past 36 months and "existing products" refers to products we have sold commercially for more than 36 months. Certain financial information is presented on a rounded basis, which may cause minor differences. Segment results and commentary exclude the impact of discontinued operations. NOTES ON NON-GAAP FINANCIAL MEASURES We report our financial results in accordance with accounting principles generally accepted in the United States, commonly referred to as “GAAP.” In this press release, we provide supplemental information, consisting of the following non-GAAP financial measures: constant currency revenue growth and adjusted diluted earnings per share. These non-GAAP measures are described in more detail below. Management uses these financial measures to assess Teleflex’s financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies. Tables reconciling changes in historical constant currency net revenues to historical GAAP net revenues are set forth above under “Net Revenue by Segment" and "Net Revenue by Global Product Category". Tables reconciling historical adjusted diluted earnings per share from continuing operations to historical GAAP diluted earnings per share from continuing operations are set forth below. Constant currency revenue growth: This non-GAAP measure is based upon net revenues, adjusted to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends. Adjusted diluted earnings per share: This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the items described below. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends. Restructuring, restructuring related and impairment items - Restructuring programs involve discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies and integrate acquired businesses. Depending on the specific restructuring program involved, our restructuring charges may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement and other exit costs associated with the restructuring program. Restructuring related charges are directly related to our restructuring programs and consist of facility consolidation costs, including accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of the restructuring program. Impairment charges occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results. Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; legal entity restructuring expense; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; and bridge loan facility and backstop financing fees in connection with loan facilities that ultimately were not utilized. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities. Other items - These are discrete items that occur sporadically and can affect period-to-period comparisons. See footnote C to the reconciliation tables set forth below. European medical device regulation - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. Manufacturers of currently marketed medical devices will have until May 2021 to meet the MDR requirements, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until May 2024, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD). Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions. Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability. RECONCILIATION OF CONSOLIDATED STATEMENT OF INCOME ITEMS Dollars in millions, except per share amounts Quarter Ended - December 31, 2020 Cost of goods sold Selling, general and administrative expenses Research and development expenses Restructuring and impairment charges Income taxes Income (loss) from continuing operations Diluted earnings per share from continuing operations GAAP Basis$327.6 $232.9 $33.8 $21.8 ($0.0) $76.6 $1.62 Adjustments Restructuring, restructuring related and impairment items (A)7.1 0.4 — 21.8 1.8 27.5 $0.58 Acquisition, integration and divestiture related items (B)0.3 20.4 — — 0.5 20.2 $0.43 Other items (C)— 0.6 — — 0.1 0.5 $0.01 MDR (D)— — 3.8 — (0.0) 3.9 $0.08 Intangible amortization expense (E)21.2 18.7 0.1 — 5.5 34.6 $0.73 Tax adjustments— — — — 9.5 (9.5) $(0.20) Adjusted basis$299.0 $192.9 $29.8 $— $17.3 $153.7 $3.25 RECONCILIATION OF CONSOLIDATED STATEMENT OF INCOME ITEMS Dollars in millions, except per share amounts Quarter Ended - December 31, 2019 Cost of goods sold Selling, general and administrative expenses Research and development expenses Restructuring and impairment charges (Gain)/Loss on sale of business and assets Loss on extinguishment of debtIncome taxes Income (loss) from continuing operations Diluted earnings per share from continuing operations GAAP Basis$303.2 $220.1 $31.1 $1.9 $(2.2) $8.8 $(6.5) $107.8 $2.28 Adjustments Restructuring, restructuring related and impairment items (A)5.0 0.3 (0.0) 1.9 — — 1.1 6.1 $0.13 Acquisition, integration and divestiture related items (B)— 13.5 — — (2.2) — (0.9) 12.1 $0.26 Other items (C)— 0.3 — — — 8.8 2.1 7.0 $0.15 MDR (D)— — 1.6 — — — — 1.6 $0.03 Intangible amortization expense (E)20.5 16.7 0.1 — — — 5.0 32.3 $0.68 Tax adjustments— — — — — — 12.1 (12.1) $(0.26) Adjusted basis$277.7 $189.3 $29.5 $— $— — $12.9 $154.7 $3.28 (A) Restructuring, restructuring related and impairment items - For the three months ended December 31, 2020, pre-tax restructuring charges were $0.4 million; pre-tax restructuring related charges were $7.5 million; and pre-tax impairment charges were $21.4 million. For the three months ended December 31, 2019, pre-tax restructuring charges were $1.8 million; pre-tax restructuring related charges were $5.3 million; and pre-tax impairment charges were $0.1 million. (B) Acquisition, integration and divestiture related items - For the three months ended December 31, 2020, these charges primarily related to contingent consideration liabilities; reversal of previously recognized income related to a distributor conversion in Japan; and charges primarily related to our acquisition of Z-Medica, LLC. For the three months ended December 31, 2019, these charges primarily related to contingent consideration liabilities; and our acquisition of IWG High Performance Conductors, Inc., partially offset by the gain on sale of an asset. There were no divestiture related activities for the three months ended December 31, 2020 and December 31, 2019. (C) Other items - For the three months ended December 31, 2020, other items included expenses associated with a franchise tax audit. For the three months ended December 31, 2019, other items included debt modification costs and product relabeling costs. (D) MDR - These costs were associated with our efforts to comply with the European Medical Device Regulation. (E) Intangible amortization expense - For the three months ended December 31, 2020, intangible asset amortization expense of $21.2 million is included in cost of goods sold. For the three months ended December 31, 2019, we reclassified intangible asset amortization expense of $20.5 million, respectively, from selling, general and administrative expenses to cost of goods sold for comparability. RECONCILIATION OF CONSOLIDATED STATEMENT OF INCOME ITEMS Dollars in millions, except per share amounts Year Ended - December 31, 2020 Cost of goods sold Selling, general and administrative expenses Research and development expenses Restructuring and impairment charges Income taxes Income (loss) from continuing operations Diluted earnings per share from continuing operations GAAP Basis$1,212.3 $743.6 $119.7 $38.5 $21.9 $335.8 $7.10 Adjustments Restructuring, restructuring related and impairment items (A)25.9 0.9 — 38.5 3.0 62.3 $1.32 Acquisition, integration and divestiture related items (B)3.6 (30.4) — — 1.2 (28.0) $(0.59) Other items (C)— 1.1 — — 0.3 0.8 $0.02 MDR (D)— — 11.3 — 0.0 11.3 $0.24 Intangible amortization expense (E)84.4 73.8 0.4 — 24.4 134.3 $2.84 Tax adjustments— — — — 12.0 (12.0) $(0.25) Adjusted basis$1,098.4 $698.2 $108.0 $— $62.7 $504.5 $10.67 RECONCILIATION OF CONSOLIDATED STATEMENT OF INCOME ITEMS Dollars in millions, except per share amounts Year Ended - December 31, 2019 Cost of goods sold Selling, general and administrative expenses Research and development expenses Restructuring and impairment charges (Gain)/Loss on sale of business and assetsLoss on extinguishment of debtIncome taxes Income (loss) from continuing operations Diluted earnings per share from continuing operations GAAP Basis$1,186.4 $851.8 $113.9 $22.2 $(6.1)$8.8 $(122.1) $462.0 $9.81 Adjustments Restructuring, restructuring related and impairment items (A)15.9 0.4 0.0 22.2 — — 5.1 33.4 $0.71 Acquisition, integration and divestiture related items (B)0.1 55.3 — — (6.1)— (2.8) 52.1 $1.11 Other items (C)— 1.8 — — — 8.8 2.5 8.2 $0.17 MDR (D)— — 3.2 — — — — 3.2 $0.07 Intangible amortization expense (E)82.6 66.9 0.4 — — — 28.1 121.9 $2.59 Tax adjustments— — — — — — 155.8 (155.8) $(3.31) Adjusted basis$1,087.8 $727.3 $110.2 $— $— — $66.5 $525.0 $11.15 (A) Restructuring, restructuring related and impairment items - For the twelve months ended December 31, 2020, pre-tax restructuring charges were $17.1 million; pre-tax restructuring related charges were $26.7 million; and pre-tax impairment charges were $21.4 million. For the twelve months ended December 31, 2019, pre-tax restructuring charges $15.2 million; pre-tax restructuring related charges were $16.3 million; and pre-tax impairment charges were $7.0 million. (B) Acquisition, integration and divestiture related items - For the twelve months ended December 31, 2020, these items primarily related to the reversal of contingent consideration liabilities, partially offset by charges primarily related to our acquisitions of IWG High Performance Conductors, Inc. and Z-Medica, LLC, and the reversal of previously recognized income related to a distributor conversion in Japan. For the twelve months ended December 31, 2019, these charges primarily related to contingent consideration liabilities and our acquisitions of IWG High Performance Conductors, Inc. and Essential Medical, Inc., partially offset by the gain on sale of a business and another asset. There were no divestiture related activities for the twelve months ended December 31, 2020 and December 31, 2019. (C) Other items - For the twelve months ended December 31, 2020, other items included expenses associated with a franchise tax audit and prior year tax matters. For the twelve months ended December 31, 2019, other items included debt modification costs, expenses associated with a franchise tax audit, and product relabeling costs, somewhat offset by a credit associated with an insurance settlement. (D) MDR - These costs were associated with our efforts to comply with the European Medical Device Regulation. (E) Intangible amortization expense - For the year ended December 31, 2020, intangible asset amortization expense of $84.4 million is included within cost of goods sold. For the year ended December 31, 2019, we reclassified intangible asset amortization expense of $82.6 million, respectively, from selling, general and administrative expenses to cost of goods sold for comparability. ABOUT TELEFLEX INCORPORATED Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation - a relentless pursuit of identifying unmet clinical needs - to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com. Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift®, and Weck® - trusted brands united by a common sense of purpose. CAUTION CONCERNING FORWARD-LOOKING INFORMATION This press release contains forward-looking statements, including, but not limited to, statements regarding our confidence in our diversified product portfolio and in our ability to deliver robust revenue growth, margin expansion and adjusted earnings growth, all while investing in our business to sustain our revenue growth and profitability profile over the long-term; forecasted 2021 GAAP and constant currency revenue growth and GAAP and adjusted diluted earnings per share; and our estimates regarding the projected impact of foreign currency exchange rate fluctuations on our 2020 financial results. Actual results could differ materially from those in the forward-looking statements due to, among other things, the adverse economic conditions associated with the COVID-19 global health pandemic and the associated financial crisis, stay-at-home and other orders, which may significantly reduce customer spending and which may have a negative impact on the Company’s business, changes in business relationships with and purchases by or from major customers or suppliers; delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to provide products to our customers, which may be due to, among other things, events that impact key distributors, suppliers and third-party vendors that sterilize our products; our inability to integrate acquired businesses into our operations, realize planned synergies and operate such businesses profitably in accordance with our expectations; the inability of acquired businesses to generate revenues in accordance with our expectations; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of enacted tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, sovereign debt issues and the impact of the United Kingdom's departure from the European Union, commonly known as "Brexit"; public health epidemics; difficulties in entering new markets; general economic conditions; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our most recently filed Annual Report on Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation. TELEFLEX INCORPORATED CONSOLIDATED STATEMENTS OF INCOME Three Months Ended Twelve Months Ended December 31, 2020 December 31, 2019 December 31, 2020 December 31, 2019 (Dollars and shares in thousands, except per share)Net revenues$711,179 $680,952 $2,537,156 $2,595,362 Cost of goods sold327,625 303,230 1,212,282 1,186,357 Gross profit383,554 377,722 1,324,874 1,409,005 Selling, general and administrative expenses232,906 220,054 743,568 851,766 Research and development expenses33,769 31,128 119,747 113,857 Restructuring and impairment charges21,799 1,857 38,491 22,205 Gain on sale of assets— (2,249) — (6,077)Income from continuing operations before interest, loss on extinguishment of debt and taxes95,080 126,932 423,068 427,254 Interest expense18,721 17,275 66,494 80,270 Interest income(202) (460) (1,158) (1,741)Loss on extinguishment of debt— 8,822 — 8,822 Income from continuing operations before taxes76,561 101,295 357,732 339,903 Taxes (benefit) on income from continuing operations(40) (6,511) 21,931 (122,078)Income from continuing operations76,601 107,806 335,801 461,981 (Loss) income from discontinued operations(610) 463 (621) (828)(Benefit) taxes on (loss) income from discontinued operations(140) 4 (144) (313)(Loss) income on discontinued operations(470) 459 (477) (515)Net income$76,131 $108,265 $335,324 $461,466 Earnings per share: Basic: Income from continuing operations$1.64 $2.33 $7.22 $10.00 (Loss) income on discontinued operations(0.01) 0.01 (0.01) (0.01)Net income$1.63 $2.34 $7.21 $9.99 Diluted: Income from continuing operations$1.62 $2.28 $7.10 $9.81 (Loss) income on discontinued operations(0.01) 0.01 (0.01) (0.01)Net income$1.61 $2.29 $7.09 $9.80 Weighted average shares outstanding: Basic46,599 46,333 46,488 46,200 Diluted47,343 47,207 47,287 47,090 TELEFLEX INCORPORATED CONSOLIDATED BALANCE SHEETS December 31, 2020 2019 (Dollars and shares in thousands, except per share)ASSETSCurrent assets Cash and cash equivalents$375,880 $301,083 Accounts receivable, net395,071 418,673 Inventories513,196 476,557 Prepaid expenses and other current assets115,436 97,943 Prepaid taxes22,842 12,076 Total current assets1,422,425 1,306,332 Property, plant and equipment, net473,912 430,719 Operating lease assets100,635 113,160 Goodwill2,585,966 2,245,305 Intangibles assets, net2,519,746 2,156,285 Deferred tax assets8,073 5,572 Other assets41,802 52,447 Total assets$7,152,559 $6,309,820 LIABILITIES AND EQUITY Current liabilities Current borrowings$100,500 $50,000 Accounts payable102,520 102,916 Accrued expenses136,276 100,466 Current portion of contingent consideration20,543 148,090 Payroll and benefit-related liabilities122,366 115,981 Accrued interest7,135 5,514 Income taxes payable17,361 6,692 Other current liabilities33,326 33,396 Total current liabilities540,027 563,055 Long-term borrowings2,377,888 1,858,943 Deferred tax liabilities484,678 439,558 Pension and postretirement benefit liabilities74,499 82,719 Noncurrent liability for uncertain tax positions10,127 10,294 Noncurrent contingent consideration16,090 71,818 Noncurrent operating lease liabilities86,097 101,372 Other liabilities226,696 202,741 Total liabilities3,816,102 3,330,500 Commitments and contingencies Shareholders’ equity Common shares, $1 par value Issued: 2020 — 47,812 shares; 2019 — 47,536 shares47,812 47,536 Additional paid-in capital652,305 616,980 Retained earnings3,096,228 2,824,916 Accumulated other comprehensive loss(297,298) (344,392) 3,499,047 3,145,040 Less: Treasury stock, at cost162,590 165,720 Total shareholders' equity3,336,457 2,979,320 Total liabilities and shareholders' equity$7,152,559 $6,309,820 TELEFLEX INCORPORATED CONSOLIDATED STATEMENTS OF CASH FLOWS Year ended December 31, 2020 2019 (Dollars in thousands)Cash flows from operating activities of continuing operations: Net income$335,324 $461,466 Adjustments to reconcile net income to net cash provided by operating activities: Loss (Income) from discontinued operations477 515 Depreciation expense68,567 64,088 Intangible asset amortization expense158,685 149,974 Deferred financing costs and debt discount amortization expense4,430 4,307 Loss on extinguishment of debt— 8,822 Fair value step up of acquired inventory sold1,707 — Changes in contingent consideration(38,164) 53,915 Asset impairments21,388 6,966 Stock-based compensation20,739 26,940 Net gain on sales of businesses and assets— (6,077)Deferred income taxes, net(32,675) (168,594)Payments for contingent consideration(79,801) (26,092)Interest benefit on swaps designated as net investment hedges(19,178) (18,866)Other(26,636) (5,800)Changes in operating assets and liabilities, net of effects of acquisitions and disposals: Accounts receivable44,748 (59,793)Inventories(5,497) (53,170)Prepaid expenses and other current assets(4,323) (31,023)Accounts payable, accrued expenses and other liabilities646 36,021 Income taxes receivable and payable, net(13,294) (6,531)Net cash provided by operating activities from continuing operations437,143 437,068 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment(90,694) (102,695)Payments for businesses and intangibles acquired, net of cash acquired(767,830) (3,462)Proceeds from sales of businesses and assets1,400 14,345 Net interest proceeds on swaps designated as net investment hedges19,341 18,331 Net cash used in investing activities from continuing operations(837,783) (73,481)Cash flows from financing activities of continuing operations: Proceeds from new borrowings1,513,807 275,000 Reduction in borrowings(938,807) (528,500)Debt extinguishment, issuance and amendment fees(8,440) (11,635)Proceeds from share based compensation plans and the related tax impacts18,994 21,206 Payments for contingent consideration(67,170) (112,079)Dividends(63,221) (62,828)Net cash provided by (used in) financing activities from continuing operations455,163 (418,836)Cash flows from discontinued operations: Net cash (used in) provided by operating activities(737) 2,457 Net cash (used in) provided by discontinued operations(737) 2,457 Effect of exchange rate changes on cash and cash equivalents21,011 (3,286)Net increase (decrease) in cash and cash equivalents74,797 (56,078)Cash and cash equivalents at the beginning of the year301,083 357,161 Cash and cash equivalents at the end of the year$375,880 $301,083 Jake Elguicze Treasurer and Vice President of Investor Relations 610-948-2836